TMS at a Glance

1. FDA-cleared for treatment of major depressive disorder, obsessive-compulsive disorder, and smoking cessation
2. Likelihood of patients with MDD achieving remission is limited and declines with each successive medication trial. Patients who have undergone two medication trials have approximately a 16 percent chance of remission with a new trial.* Studies show the following TMS rates**:
   62% Response     41% Remission     62.5% Durability ***
3. Appropriate for use either as an adjunct therapy or as a monotherapy
4. Well-tolerated, non-invasive, and low-risk treatment for MDD, requiring no post-treatment downtime. Occasional side effects (scalp sensitivity or headaches)
5. Performed in an office setting. Average treatment plan usually consists of 20-minute treatment sessions performed five days each week for six consecutive weeks
6. Covered by most major insurance; Medicaid and Medicare accepted in select locations (Call 1-855-940-4867 for more information.)
7. Works via magnetic pulses that induce electrical currents, stimulating neurons to bring about therapeutic effect. TMS for MDD targets the left dorsolateral prefrontal cortex. TMS for OCD delivers bilateral stimulation to the medial prefrontal cortex and cingulate cortex.
8. Possible Contraindications:
   - History of seizures
   - Implanted medical devices like a pacemaker
   - Non-removable metallic implants above the neckline

* StarD Study; Rush et al., Am. J Psychiatry 2006, PMID 17074942
** A Multisite, Naturalistic, Observational Study of TMS; Dunner et al., J Clin Psychiatry 2014, PMID 25271871
*** 12-mo follow-up measured via IRS-SR scale with a cohort of 120 patients